Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.64 |
| ▸ | NPC1 | O15118 | 6/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12136194 | 0.86 | RAB9A (0.68) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL9698171 | 0.85 | RAB9A (0.62) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL5454201 | 0.85 | ALDH1A1 (0.70) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL6204453 | 0.85 | RAB9A (0.62) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL5458651 | 0.82 | SMN1; SMN2 (0.59) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL9696974 | 0.79 | RAB9A (0.55) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL5811766 | 0.78 | RAB9A (0.62) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL7850067 | 0.76 | RAB9A (0.62) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL10247484 | 0.75 | RAB9A (0.51) | RAB9ASMN1; SMN2NPC1LMNATP53 | |
| SCHEMBL7952319 | 0.75 | PSMD14 (0.54) | RAB9ASMN1; SMN2LMNATP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969577-B2 | Curable composition comprising a thermolatent base | BASF SE (DE) | 2015-03-03 | — | — | US | disclosed |
| US-20110245375-A1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | BASF SE (DE) | 2011-10-06 | — | — | US | disclosed |
| EP-1983992-A2 | 2-IMINO-BENZIMIDAZOLES | Abbott Laboratories (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| WO-2007084728-A2 | 2-IMINO-BENZIMIDAZOLES | ABBOTT LABORATORIES (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007084728-A2 | 2-IMINO-BENZIMIDAZOLES | ABBOTT LABORATORIES (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245375-A1 | CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE | COIL, MAPT, ASH2L | RAB9A 1773/4885SMN1; SMN2 1451/4885NPC1 4620/4885 |
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | RAB9A 1111/4885SMN1; SMN2 824/4885NPC1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.